Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1101-1120 of 2,120 trials

Hepatocellular Carcinoma: Triple Treatment Study

We are studying a combination of three medications for patients with non-resectable liver cancer. The goal is to see if this approach improves symptoms and quality of life compared to past treatments.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHepatologyOncology

Rheumatoid Arthritis: Baricitinib and Anti-TNF Combination Study

We are investigating whether combining baricitinib with anti-TNF therapy helps patients with rheumatoid arthritis who haven't responded to other treatments. The study will also look at safety and how well patients can reduce their steroid use.

Rheumatoid Arthritis6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesRheumatology

HYSTINDO Study: Indocyanine Green in Laparoscopic Hysterectomy

We are exploring how a special dye can help surgeons see blood flow in the vaginal area during laparoscopic hysterectomy. This study aims to improve surgical safety and outcomes for patients.

Total Hysterectomy>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsInternal Medicine

Early Rheumatoid Arthritis: Biomarker Study for Abatacept

We are investigating if certain biomarkers can predict how well patients with early rheumatoid arthritis respond to abatacept treatment. This may help tailor therapies to individual needs.

Rheumatoid Arthritis3-6 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Crohn's Disease in Children: Mirikizumab Study

We are studying whether Mirikizumab can help children with moderately to severely active Crohn's Disease achieve better health compared to a placebo. This research aims to improve treatment options for young patients.

Crohn's Disease1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

dTap Booster Vaccination for Health Care Workers

We are studying the immune response of health care workers to a dTap booster vaccine for pertussis, diphtheria, and tetanus. This helps us understand how well the vaccine boosts their immunity.

Diphtheria, Tetanus, and Pertussis Immunization1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Breast Cancer: Alisertib with Hormone Therapy

We are studying how well alisertib works with hormone therapy for patients with recurrent or metastatic hormone receptor positive, HER2 negative breast cancer. Our goal is to find the best dose and assess safety and effectiveness.

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology

Posaconazole for Fungal Infection Prevention in Stem Cell Transplant Patients

We are studying whether posaconazole can effectively prevent fungal infections in patients receiving stem cell transplants. This research aims to understand how well the medication works and its impact on patient recovery.

Healthy Participants>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious Diseases

Diabetic Ketoacidosis: Comparing Ringer Lactate and Saline

We are studying whether Ringer Lactate is more effective than isotonic saline in treating severe diabetic ketoacidosis in ICU patients. This may help improve treatment outcomes for those affected.

Diabetic Ketoacidosis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyInternal Medicine

Fanconi Anaemia: Gene Therapy Study

We are evaluating the long-term safety and effects of a gene therapy using modified cells in patients with Fanconi Anaemia Subtype A. This study aims to understand how well the treatment works and its impact on blood health over time.

Fanconi's AnemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyInternal Medicine

Advanced Solid Tumors: ART0380 Oral Treatment

We are studying the safety and effectiveness of the oral medication ART0380 for patients with advanced or metastatic solid tumors. This includes testing it alone and in combination with other drugs to see how well it works.

Advanced or Metastatic Solid TumoursSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: Abatacept and Daratumumab Treatment

We are studying a combination of two medications to see if it is safe and effective for people with rheumatoid arthritis who have specific antibodies. This research aims to explore new ways to manage autoimmunity in these patients.

Rheumatoid Arthritis6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Advanced Cancer: IO102-IO103 with Pembrolizumab

We are studying a new treatment combination for patients with metastatic non-small cell lung cancer, squamous cell carcinoma of the head and neck, or metastatic urothelial bladder cancer. The goal is to evaluate its effectiveness and safety as a first-line therapy.

Metastatic Squamous Cell Carcinoma of Head and NeckMetastatic Urothelial Bladder CancerMetastatic Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesOncology

Multiple Myeloma: Selinexor with Dexamethasone and Bortezomib

We are studying different combinations of Selinexor, Dexamethasone, and Bortezomib for patients with hard-to-treat multiple myeloma. Our goal is to see how well these treatments work and how safe they are.

Multiple MyelomaRelapsed/Refractory Multiple MyelomaPenta-Refractory Multiple Myeloma3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Locally-Advanced Rectal Cancer: Tailored Treatment Study

We are studying a personalized treatment plan for patients with locally-advanced rectal cancer who respond well to initial chemotherapy. The goal is to see if this approach maintains effective surgery outcomes while reducing treatment intensity.

Rectal Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Alzheimer's Disease: Understanding Tau Spread and Language Function

We are studying how tau protein spreads in the brain during different stages of Alzheimer's disease and its impact on language abilities. This research may help us understand cognitive changes in patients.

Early Alzheimer's Disease>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesNeurologyPsychiatry

Sodium Thiosulfate Injections for Ectopic Calcifications

We are studying whether injections of sodium thiosulfate can help reduce calcifications and ossifications in patients with certain autoimmune conditions. This trial will also look at the treatment's safety and its impact on pain and quality of life.

Ectopic Calcification and Ossification>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyRheumatology

Daratumumab for Very High-Risk T-Cell Acute Lymphoblastic Leukemia

We are studying whether adding daratumumab to standard treatment helps adults with very high-risk T-ALL achieve better disease control. This trial will also assess the safety and effectiveness of this combination therapy.

Very High-Risk T-Lineage Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Hodgkin's Lymphoma: Atezolizumab and BEGEV Treatment

We are studying a new combination treatment for patients with relapsed or refractory Hodgkin's lymphoma to see if it helps improve response rates before stem-cell transplantation. This trial will also evaluate the safety and tolerability of this treatment approach.

Hodgkin's Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Mantle Cell Lymphoma: Loncastuximab Tesirine Treatment

We are studying whether loncastuximab tesirine can improve outcomes for patients with relapsed or refractory mantle cell lymphoma after immunochemotherapy. The trial also looks at the safety of this treatment and its effectiveness in reducing disease presence.

Mantle Cell LymphomaEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology